Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
DR. DAVID DALTON
Dr. David Dalton is Chairman, President and CEO of Univec Inc. and subsidiary Physician and Pharmaceutical Services Inc. (PPSI). Dr. David Dalton has spent his professional career in the pharmaceutical industry, bringing over 35 years of experience to his profession. He received a B.S. in pharmacy from West Virginia in 1971 and was honored as one of the top ten graduates over a 100 - year span. Dr.Dalton became a Doctor of Pharmacy in 1974. He served in several capacities with Rite Aid Corporation from 1971 to 1989 including Corporate Vice President. He left Rite Aid Corporation to acquire Peoples Drug Stores with an investment Group inclusive of Robert Bass of Texas. Dr. Dalton served as Senior Vice President.
Dr. Dalton then acquired Sherman Management Group, one of the first worker compensation pharmacy benefit management companies in the United States and Medical Service Agency, where he served as Chairman, President, and CEO, which he merged in November of 1994 to
MEDNET, a national Pharmacy Benefit Management Company (PBM) listed on NASDAQ. Dr. Dalton served as Executive Vice President of MEDNET and President of Medi-Claim (a wholly owned subsidiary of MEDNET). Dr. Dalton’s next venture, Managed Care Rx, a National Specialty care pharmaceutical provider for assisted living facilities, nursing homes, and prisons, was merged with, a subsidiary of Bergen Brunswick, a drug wholesale company with sales in excess of 14 billion.
His next venture, Health Resources, Inc. for which he is Founder, President and CEO is a national pharmacy benefit management company that has contracted with over 50,000 retail pharmacies for the fulfillment of prescription orders and Pharmacy Services, Inc. a nationwide prescription mail service company.
Dr. Dalton is one of the original members and directors of the National Council of Prescription Drug Programs (NCPDP) and responsible for the standards that pharmacies use across the United States to transmit prescriptions.
Dr. Dalton has served as a board member on such organizations as Blue Shield of Pennsylvania,
United Way, National Health Association, National Association of Chain Drug Stores, (NACDS) .
He has been a visiting professor and lectures at several schools of pharmacy throughout the United States and Past President of West Virginia University School of Pharmacy Presidential Committee. Dr. Dalton has received national and local recognition by the President and Senate of the United States including the Medal of Freedom the highest honor given by the United States Senate. In addition the University of West Virginia recognized him as a Distinguished Alumni and again honored him as Outstanding Alumni of West Virginia School of Pharmacy and Outstanding Service recognition to the School of Pharmacy of West Virginia University. Dr.Dalton was inducted into the Black CEO Hall of Fame in 2006
http://univecinc.com/About.html
Newbies - Univec Inc. announces FDA approval of labeler code.
Aug 12, 2011
OTC Disclosure & News Service
Owings Mills, MD -
univec inc.
The Specialty Pharmaceutical Company
FOR IMMEDIATE
RELEASE
Contact:
Investor relations: David Dalton, President
E-mail univec@univecinc.com
UNIVEC announces FDA approval of Labeler Code.
Owings Mills, Maryland —August 8, 2011– Univec, Inc. (UNVC) a specialty pharmaceutical company, announces it has been issued a FDA labeler code. This is the prefix for each National Drug Code (NDC) on products that is manufactured and distributed by Univec for the company’s Specialty Pharmaceuticals. The National Drug Code is a unique identifier assigned by the FDA to identify the manufacturer of a prescription drug product intended for human use. The NDC number is also used in the electronic claim processing for payment by third party entities and e-prescribing for physicians.
David L. Dalton, President and CEO of Univec stated. “ We are delighted to make progress in our new business model. The National Drug Codes are very important not only from the standpoint of the FDA, but it also allows payment from Medicare, Medicaid, Insurance companies and other third party payment systems. This is another milestone reached in placement of a solid foundation to build and grow the company. We thank our associates, shareholders and investors for the support and confidence they have shown the company. ”
About Univec
Univec, Inc. A minority business enterprise (MBE) is a Specialty Pharmaceutical Company that manufactures and distributes high cost Specialty Pharmaceuticals. Specialty Pharmaceuticals are high cost products that are not usually dispensed in retail pharmacies but require special handling and a complex pharmaceutical regime. The company is focused on diseases such as Sickle Cell Anemia, Cancer, HIV/Aids, Hepatitis C., Multiple Sclerosis, Hemophilia and Drug addiction.
PPSI (PHYSICIAN AND PHARMACEUTICAL SERVICES, INC.) a subsidiary of Univec promotes and pays for pharmaceutical products though its network of pharmacies. PPSI eliminates the need for the pharmaceutical companies to distribute actual drug samples to physicians reducing potential liability for the physician while maintaining clinical oversight and drug interaction checks for the patient. The company through it’s “StarterScript” allows in lieu of a physician sample, a voucher or a co-payment card to be provide to the patient for a trial supply of medication redeemed in any of the nearly 55,000 retail pharmacies utilizing the PPSI real-time processing system.
Forward Looking Statements
This document may contain forward-looking statements based on current expectations that could be affected by the risks and uncertainties involved in Univec’s business. These risks and uncertainties include, but are not limited to, the risks described from time to time in Univec’s reports to the General Public and reporting agencies. Subsequent written or oral statements attributable to Univec or persons acting on its behalf are expressly qualified in their entirety by the cautionary statements in this document and those in Univec’s reports filed
-End-
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
Univec has patents, Labeler Code, FDA Approval, what are we waiting for now??
JGygli
When do you think things will start happening here.
JGygli, great posts
With all these patent approvals Univec received on medical products how does this incorporate into the latest press release announcing FDA approval on the Labeler code?
If Univec already has the products and now the Labeler code what's the next step.. sales? revenue time?
Good findings!
Good posts lowman/lucky. Let's discuss what could potentially be in store for us here since this Labeler code is done. Now what?
very good post makes sense!
If UNVC had a bit more buying pressure when we started heading north from .004+ shorts just might have started covering their positions causing a surge of buying which could have resulted in .01+ run here. This really adds up now as i noticed every time UNVC is on a run and about to breakout a huge smack down comes right at the top. Univec will just need to bring it to the table next time to get the shorties to cover and start building a solid foundation!
lowman,
This is what i am showing for short interest
http://www.otcmarkets.com/stock/UNVC/short-sales
Aug 15, 2011 0 -100.00 24,492,613 0.00 No No
Jul 29, 2011 4,554 100.00 7,854,713 1.00 No No
Jun 30, 2011 0 -100.00 797,632 0.00 No No
Jun 15, 2011 11,761 100.00 393,557 1.00 No No
May 13, 2011 0 -100.00 1,933,707 0.00 No No
Apr 29, 2011 84,667 100.00 3,890,608 1.00 No No
Feb 15, 2011 0 -100.00 1,847,475 0.00 No No
Jan 31, 2011 5,433 100.00 3,886,253 1.00 No No
Jan 30, 2009 0 -100.00 800 0.00 No No
Jan 15, 2009 422,291 100.00 92,229 4.58 No No
Correct me if I'm wrong but it seems like virtually not much shorting at all to me? Also, if there was major shorting typically you get a few bashers on the message forum, i haven't seen any.
Where do you see heavy short selling taking place?
Not good - WARNING LETTER
CERTIFIED MAIL
RETURN RECEIPT REQUESTED
W/L 40-11
May 13, 2011
Mr. William P. Mountanos, CEO
Nuvonyx, Inc. DBA Real Aloe, Inc. and U.S. Aloe
2045 Corte Del Nogal
Carlsbad, CA 92011
Dear Mr. Mountanos:
On October 18 through October 21, 2010 and January 10 through January 20, 2011, the U.S. Food and Drug Administration (FDA) inspected your firm located in Carlsbad, CA. Your firm manufactures, packages, labels, and holds dietary supplements. The inspection identified significant violations of Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling or Holding Operations for Dietary Supplements (CGMP) regulations, Title 21, Code of Federal Regulations (CFR) Part 111 (21 CFR Part 111).
These violations cause your dietary supplement products AloeAdvanced and AloeControl to be adulterated within the meaning of Section 402(g)(1) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 342(g)(1)] in that the dietary supplements have been prepared, packed, or held under conditions that do not meet CGMP regulations for dietary supplements. These observations were presented to you in a FDA-483 at the conclusion of our inspection on October 21, 2010. During our January 2011 inspection, our investigator verified that these violations have not been corrected.
The inspection revealed the following violations:
1. Your firm failed to conduct appropriate testing of finished batches of dietary supplements to determine whether such dietary supplements met established specifications for identity, purity, strength, and composition, as required by 21 CFR 111.75(c).
Specifically, you failed to test your AloeControl (batch # (b)(4)) and AloeAdvanced (batch # (b)(4)) dietary supplements to verify that they met finished product specifications for identity, purity, strength, and composition. Your statements and the records provided to our investigator show that you performed (b)(4) tests on these batches of finished products, but this type of test does not verify the identity, purity, strength, and composition of the finished product, as required by 21 CFR 111.75(c).
2. Your firm failed to establish component specifications that are necessary to ensure that specifications for the identity, purity, strength, and composition of dietary supplements manufactured using the components are met, as required by 21 CFR 111.70(b)(1) and (b)(2).
Specifically, you did not establish component specifications for any components used in your AloeAdvanced and AloeControl dietary supplements. During our October 2010 inspection, you indicated you would take corrective action by January 1, 2011. However, our recent inspection from January 10-20, 2011 revealed that corrections were not made.
3. Your firm failed to conduct at least one appropriate test or examination to verify the identity of a component that is a dietary ingredient, prior to its use, as required by 21 CFR 111.75(a)(1)(i).
Specifically, your firm uses dietary ingredients such as ecklonia cava kelp, gymnema sylvestre, and Vitamin C in your AloeAdvanced Dietary Supplement and chromium piccolinate, Co10, Pancreatin, Conjugated Linoleic Acid, Green Tea and Vitamin C in your AloeControl Dietary Supplement; however, our investigator found that you did not conduct identity testing on any dietary ingredients, but instead relied on (b)(4) from your suppliers. (b)(4) from suppliers do not fulfill the requirements of 21 CFR 111.75(a)(1)(i) for dietary ingredients. The regulations require you to conduct identity testing or examination for dietary ingredients.
4. Your firm failed to qualify suppliers of components other than dietary ingredients by establishing the reliability of the suppliers’ COA through confirmation of the results of the suppliers’ tests or examinations, as required by 21 CFR 111.75(a)(2)(A).
Specifically, our investigator found that you sent out (b)(4) to your suppliers who provide you with a (b)(4) to “validate” the use of the (b)(4). However, this is inadequate because it does not show that you confirm the results of the suppliers’ tests or examinations.
5. Your firm failed to establish and follow written procedures for the responsibilities of the quality control operations, including written procedures for conducting a material review and making a disposition decision, and for approving or rejecting any reprocessing, as required by 21 CFR 111.103. Our investigator found that you had no written procedures for your firm’s quality control operations.
6. Your firm failed to make and keep records that show that water, when used in a manner such that the water may become a component of the dietary supplement, meets the requirements of 21 CFR 111.15(e)(2), as required by 21 CFR 111.23(c).
Specifically, our investigator found that your firm did not make records to show that the (b)(4) water used in your AloeAdvanced and AloeControl products complies with applicable Federal, State, and local requirements and does not contaminate the dietary supplements.
This letter is not an all-inclusive list of violations at your facility. It is your responsibility to ensure that your establishment and the products you market comply with the Act and its implementing regulations. Failure to promptly correct the violations specified above may result in enforcement action without further notice. Enforcement action may include seizure of violative products and/or injunction against the manufacturers and distributors of violative products.
Please advise this office in writing within 15 working days from your receipt of this letter of the specific steps you have taken to correct the violations noted above and to ensure that similar violations do not occur in the future. Your response should include any documentation necessary to show that correction has been achieved. If you cannot complete all corrections before you respond, state the reason for the delay and the date by which you will complete the corrections.
Your response should be sent to:
Blake Bevill
Director, Compliance Branch
Food and Drug Administration
Los Angeles District Office
19701 Fairchild
Irvine, CA 92612
If you have any questions about the content of this letter, please contact Jessica Mu, Compliance Officer, at 949-608-4477.
Sincerely yours,
/s/
Alonza E. Cruse
District Director
What's interesting is that since Nov 2010 until present this ran approximately 4 times from .0007ish to .0066, .0028, .0018, .0044.
It seems every time the stock comes back to about .0007 and all the flippers are out they run this up fast in a one/two day event.
So is this just a flipper stock you need to have patience with or is something really brewing here?
From all my findings i believe something real is actually developing, i could of sold several times to make a nice buck but am still holding. I rather see long term gains when this turns into something real and don't want to kick myself for selling out early. I could be wrong, this will be interesting to see how it plays out.
I couldn't agree more, from reading the latest financials it seems like they are getting ready for something here (obviously we all went to see it happen asap) but seems Univec takes their time and flippers/day traders move on. I been here since November 2010 still here to stay and see what develops.
I think this Labeler code PR was more along the lines to say "ok were actually doing something here and keep an eye on us". Guess we shall see.
So Univec now has a Labeler code!
What's their game plan now, roll out existing products or new products? From looking over their press releases from 2003-2004 they were obviously doing something right at one time which the current price per share was around .06-.14 and they did 2.2 Million in sales. Can we expect to see these levels again?
*
UNIVEC Selected by Johns Hopkins
BALTIMORE -- Univec, Inc. (OTCBB: UNVC) a specialty pharmaceutical, auto-disabled and safety syringe healthcare organization announced that it...
Business Wire, 11/21/05 · More from publication
*
Univec Announces Completion of Vista-Pharm Joint Venture
BALTIMORE -- Univec, Inc. (OTCBB: UNVC) a pharmaceutical, pre-filled and safety syringe healthcare organization announces joint venture completed...
Business Wire, 04/07/05 · More from publication
*
UNIVEC Named One of Maryland's Fastest Growing Technology Companies in Deloitte Technology Fast 50 Program; Ranked #19 out of 50 with Annual Growth of 382%
BALTIMORE -- UNIVEC, Inc., a Baltimore, Md. based medical pharmaceutical services company (OTCBB: UNVC) has been named to Deloitte's prestigious...
Business Wire, 10/14/04 · More from publication
*
Univec Announced Record Sales for the Year
Business Editors
Business Editors
BALTIMORE--(BUSINESS WIRE)--May 19, 2004
Univec, Inc. (OTCBB: UNVC) a pharmaceutical,...
Business Wire, 05/19/04 · More from publication
*
Univec Announces Change of Trading Symbol
Business Editors/Health/Medical Writers
Business Editors/Health/Medical Writers
BALTIMORE--(BUSINESS WIRE)--April 20, 2004
...
Business Wire, 04/20/04 · More from publication
*
Security Biometrics, Inc. Subsidiary eMedRx, Forms Exclusive Strategic Alliance With Univec
Business Editors/Health/Medical Writers
Business Editors/Health/Medical Writers
BALTIMORE & NEW YORK--(BUSINESS WIRE)--Feb. 23,...
Business Wire, 02/23/04 · More from publication
*
Univec Announces Strategic Marketing and Manufacturing Partnership with Medpro, Inc
Business Editors
Business Editors
BALTIMORE--(BUSINESS WIRE)--Feb. 11, 2004
Univec, Inc. (OTCBB:UNVC) is a global,...
Business Wire, 02/11/04 · More from publication
*
Univec Forms Strategic Alliance With eMedRx
Business Editors
Business Editors
BALTIMORE--(BUSINESS WIRE)--Feb. 2, 2004
Univec, Inc. (OTCBB: UNVC) a pharmaceutical,...
Business Wire, 02/02/04 · More from publication
*
Univec Revenues Increase Third Consecutive Quarter
Business Editors/Health/Medical Writers
Business Editors/Health/Medical Writers
BALTIMORE--(BUSINESS WIRE)--Nov. 17, 2003
...
Business Wire, 11/17/03 · More from publication
*
Univec Revenues Increase over 400% for Second Quarter
Business Editors
Business Editors
BALTIMORE--(BUSINESS WIRE)--Aug. 22, 2003
Univec, Inc. (OTCBB: UNVC) a pharmaceutical,...
Business Wire, 08/22/03 · More from publication
*
UNIVEC Announces New Executive Vice President
Business Editors
Business Editors
FARMINGDALE, N.Y.--(BUSINESS WIRE)--July 23, 2003
Univec, Inc. (OTCBB: UNVC) a...
Business Wire, 07/23/03 · More from publication
*
Univec Expected to Have Record Sales for Second Straight Quarter
Business Editors/Health/Medical Writers
Business Editors/Health/Medical Writers
FARMINGDALE, N.Y.--(BUSINESS WIRE)--July 14,...
Business Wire, 07/14/03 · More from publication
*
Univec First Quarter Revenues up 245% Over $2.2M
Business Editors
Business Editors[color=red][/color]
FARMINGDALE, N.Y.--(BUSINESS WIRE)--May 19, 2003
Univec, Inc. (OTCBB: UNVC) is an...
Business Wire, 05/19/03 · More from publication
*
Univec Enters Direct to Consumer Distribution Agreement
Business Editors
Business Editors
FARMINGDALE, N.Y.--(BUSINESS WIRE)--March 12, 2003
Univec, Inc. (OTCBB: UNVC) a...
Business Wire, 03/12/03 · More from publication
*
UNIVEC Confirms Contract Award with the State of New York
Business Editors/Health/Medical Writers
Business Editors/Health/Medical Writers
FARMINGDALE, N.Y.--(BUSINESS WIRE)--Feb. 10,...
Business Wire, 02/10/03 · More from publication
*
Univec, Inc. and McKesson Corp. Provide Approved Safety Needle for Smallpox Vaccinations
Business Editors
Business Editors
FARMINGDALE, N.Y.--(BUSINESS WIRE)--Dec. 20, 2002
Farmingdale-based Univec, Inc. (OTCBB:...
Business Wire, 12/20/02 · More from publication
Pip - your thoughts on UNVC? loaded up as you suggested and the stock has tanked the last few days.
Dalton, Chaitra chaitradalton@gmail.com
UNIVEC INC.
822 Guilford Ave.
Baltimore
Baltimore, Maryland 21202
United States
(410) 347-9959 Fax -- (410) 347-1542
Technical Contact:
Dalton, Chaitra chaitradalton@gmail.com
UNIVEC INC.
822 Guilford Ave.
Baltimore
Baltimore, Maryland 21202
United States
(410) 347-9959 Fax -- (410) 347-1542
http://univecinc.com site up.
Registrant:
UNIVEC INC.
9722 Groffs Mill Dr. Suite 116
Baltimore
Owings Mills , Maryland 21117, Maryland 21202
United States
Registered through: GoDaddy.com, Inc. (http://www.godaddy.com)
Domain Name: UNIVECINC.COM
Created on: 13-Nov-10
Expires on: 13-Nov-11
Last Updated on: 13-Nov-10
Administrative Contact:
Dalton, Chaitra chaitradalton@gmail.com
UNIVEC INC.
822 Guilford Ave.
Baltimore
Baltimore, Maryland 21202
United States
(410) 347-9959 Fax -- (410) 347-1542
Technical Contact:
Dalton, Chaitra chaitradalton@gmail.com
UNIVEC INC.
822 Guilford Ave.
Baltimore
Baltimore, Maryland 21202
United States
(410) 347-9959 Fax -- (410) 347-1542
Domain servers in listed order:
NS57.DOMAINCONTROL.COM
NS58.DOMAINCONTROL.COM
Registry Status: clientDeleteProhibited
Registry Status: clientRenewProhibited
Registry Status: clientTransferProhibited
Registry Status: clientUpdateProhibited
they haven't paid the webmaster?
weakies will sell i will scoop them up :)
1mil to buy, ask .0012 buyers up in here!
was told expect something out this week. With them updating their website now not sure what were in store for but the chart is looking healthy and think we will see nibbling back to the .002 mark until something is released.
Bluepaz, good stuff looking forward to this and all the best to you!
dam you were able to scoop up some 1's good for you! was waiting for two days just to get filled on some .0011's and .0012's. Nice base here, looking forward to seeing the website hopefully updated!
This was already holding steady for the past few months at .0008 - .001 (prior to the run). I don't think there is anywhere to plunge, only see upside from here this is the ground if you ask me.
correct! gotta love the silence. Locked and loaded can't wait for them to do their thing. I feel good things on the way.
Def agree. Being that Univec already has affiliations with many hospitals being our CEO is a doctor i think revenue will start happening much quicker then we anticipate. I been holding a while and looking to add soon as we get something on the table. Sure wish i was holding this in 03 when the company did $2.2 mil in sales, hopefully good things to come our way.
i let a few go and still have a chunk. I will start adding to my position once i see real potential and growth here. I like the share structure, business model, and CEO credentials. Now let's see something actually happen.
anyone think this could get back to .01 - .10+ what it use to trade at? Has the O/S for it.
Thanks for the heads up on UNVC can't wait :)
i tried to email and call investors relations nothing works, phone is disconnected and email kicked back. Company even in business?
hell of a earthquake out here... that was something.
Market is strong today! can this be the turn of good thing coming
I heard back from Univec looking to see something out this week.
will look to re-enter back in the .0006 - .0008s at this point.
jesh... back to triple 000's we go
Locked and loaded in UNVC patiently awaiting take off!
Im all in 2 - are you expecting news out over the wknd? I heard we could be seeing something early this week.
This is a gem buckle up :) UNVC$
i think we will see accumulation take place tomorrow (cheapies getting scooped up) as we get closer to next week!$
There is nothing negative you can say about this, some shareholders decided to take their profits early instead of holding out for what's to come, that's their call and respect it. This stock is very thin a few small buys will bring this right back over .002+ very quick. I have spoken to the CEO before and feel confident what's in store for the company. Good luck to all.
recap for newbies: Baltimore, MD, August 09, 2011 --(PR.com)-- UNIVEC announces FDA approval of Labeler Code.
Univec, Inc. (UNVC) a specialty pharmaceutical company, announces it has been issued a FDA labeler code. This is the prefix for each National Drug Code (NDC) on products that is manufactured and distributed by Univec for the company’s Specialty Pharmaceuticals. The National Drug Code is a unique identifier assigned by the FDA to identify the manufacturer of a prescription drug product intended for human use. The NDC number is also used in the electronic claim processing for payment by third party entities and e-prescribing for physicians.
David L. Dalton, President and CEO of Univec stated, "We are delighted to make progress in our new business model. The National Drug Codes are very important not only from the standpoint of the FDA, but it also allows payment from Medicare, Medicaid, Insurance companies and other third party payment systems. This is another milestone reached in placement of a solid foundation to build and grow the company. We thank our associates, shareholders and investors for the support and confidence they have shown the company."
About Univec
Univec, Inc.
A minority business enterprise (MBE) is a Specialty Pharmaceutical Company that manufactures and distributes high cost Specialty Pharmaceuticals. Specialty Pharmaceuticals are high cost products that are not usually dispensed in retail pharmacies but require special handling and a complex pharmaceutical regime. The company is focused on diseases such as Sickle Cell Anemia, Cancer, HIV/Aids, Hepatitis C., Multiple Sclerosis, Hemophilia and Drug addiction.
PPSI (Physician and Pharmaceutical Services, Inc.)
a subsidiary of Univec promotes and pays for pharmaceutical products though its network of pharmacies. PPSI eliminates the need for the pharmaceutical companies to distribute actual drug samples to physicians reducing potential liability for the physician while maintaining clinical oversight and drug interaction checks for the patient. The company through it’s "StarterScript" allows in lieu of a physician sample, a voucher or a co-payment card to be provide to the patient for a trial supply of medication redeemed in any of the nearly 55,000 retail pharmacies utilizing the PPSI real-time processing system.
Forward Looking Statements
This document may contain forward-looking statements based on current expectations that could be affected by the risks and uncertainties involved in Univec’s business. These risks and uncertainties include, but are not limited to, the risks described from time to time in Univec’s reports to the General Public and reporting agencies. Subsequent written or oral statements attributable to Univec or persons acting on its behalf are expressly qualified in their entirety by the cautionary statements in this document and those in Univec’s reports filed.
www.UnivecInc.com
The Specialty Pharmaceutical Company
Contact:
Investor relations: David Dalton, President
E-mail univec@univecinc.com
###
Contact Information
UNIVEC Inc.
David Dalton
443-253-0194
UNIVEC@UNIVECInc.com
www.UNIVECInc.com